Search By:
Products
Injury
Topic
Company
Industry
King Pharmaceuticals, Inc. may have deceptively advertised its chronic pain drug Avinza.
Investigation Source
- Nationwide
Investigation Scope
Category Information
Investigation Topics
- Misrepresentation
- Off label promotion of drug
- Deceptive Promotion Of Drug
Product or Service
- Avinza
Injury Type
- Monetary Loss
Investigation Details
Investigation of King Pharmaceuticals, Inc. concerning its prescription drug Avinza CII (morphine sulfate extended-release capsules).
King Pharmaceuticals was recently informed by the Food and Drug Administration ("FDA") that the government agency believed that King Pharmaceuticals was falsely and/or misleadingly advertising Avinza. Avinza is prescribed to treat moderate to severe chronic pain.
The FDA has stated that some of the advertising for "Avinza is false or misleading in that it presents efficacy claims for Avinza but fails to communicate and minimizes risks associated with its use, fails to present the limitations to its approved indication, and presents unsubstantiated efficacy claims."
Do not change medications without first consulting your doctor.
King Pharmaceuticals was recently informed by the Food and Drug Administration ("FDA") that the government agency believed that King Pharmaceuticals was falsely and/or misleadingly advertising Avinza. Avinza is prescribed to treat moderate to severe chronic pain.
The FDA has stated that some of the advertising for "Avinza is false or misleading in that it presents efficacy claims for Avinza but fails to communicate and minimizes risks associated with its use, fails to present the limitations to its approved indication, and presents unsubstantiated efficacy claims."
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| King Pharmaceutical, Inc. (KG) | King Pharmaceutical, Inc. is a pharmaceutical company. |